Compare · GILD vs OKYO
GILD vs OKYO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.26B, about 2903.8x OKYO ($53.5M).
- Over the past year, GILD is up 16.7% and OKYO is down 29.1% - GILD leads by 45.7 points.
- GILD has been more active in the news (17 items in the past 4 weeks vs 9 for OKYO).
- GILD has more recent analyst coverage (25 ratings vs 2 for OKYO).
- Company
- Gilead Sciences Inc.
- OKYO Pharma Limited
- Price
- $125.05+0.17%
- $1.61+1.90%
- Market cap
- $155.26B
- $53.5M
- 1M return
- -4.14%
- -3.01%
- 1Y return
- +16.66%
- -29.07%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2022
- News (4w)
- 17
- 9
- Recent ratings
- 25
- 2
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest GILD
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)
Latest OKYO
- SEC Form 3 filed by new insider Mantelli Flavio
- SEC Form 4 filed by Director Brancaccio John P
- SEC Form 4 filed by Director Denoyer Bernard
- SEC Form 4 filed by Chief Financial Officer Shah Keeren Rameshchandra
- SEC Form 4 filed by Director Simon Willy Jules
- Director Cerrone Gabriele M was granted 300,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Denoyer Bernard
- New insider Simon Willy Jules claimed ownership of 15,383 shares (SEC Form 3)
- New insider Brancaccio John P claimed ownership of 30,201 shares (SEC Form 3)
- New insider Shah Keeren Rameshchandra claimed ownership of 16,667 shares (SEC Form 3)